Gilead Sciences, Inc. (BIT:1GILD)

Gilead Sciences Statistics

Total Valuation

Gilead Sciences has a market cap or net worth of EUR 153.49 billion. The enterprise value is 165.25 billion.

Market Cap	153.49B
Enterprise Value	165.25B

Important Dates

The last earnings date was Tuesday, February 10, 2026.

Earnings Date	Feb 10, 2026
Ex-Dividend Date	Dec 12, 2025

Share Statistics

Current Share Class	1.24B
Shares Outstanding	n/a
Shares Change (YoY)	n/a
Shares Change (QoQ)	-0.08%
Owned by Insiders (%)	0.10%
Owned by Institutions (%)	89.10%
Float	1.24B

Valuation Ratios

The trailing PE ratio is 21.18 and the forward PE ratio is 16.74.

PE Ratio	21.18
Forward PE	16.74
PS Ratio	6.12
PB Ratio	7.97
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	17.99
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	22.80
EV / Sales	6.68
EV / EBITDA	13.66
EV / EBIT	16.90
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.68

Current Ratio	1.68
Quick Ratio	1.31
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	11.36

Financial Efficiency

Return on equity (ROE) is 40.66% and return on invested capital (ROIC) is 40.50%.

Return on Equity (ROE)	40.66%
Return on Assets (ROA)	12.32%
Return on Invested Capital (ROIC)	40.50%
Return on Capital Employed (ROCE)	24.65%
Weighted Average Cost of Capital (WACC)	6.38%
Revenue Per Employee	1.42M
Profits Per Employee	411,816
Employee Count	17,600
Asset Turnover	0.50
Inventory Turnover	2.05

Taxes

In the past 12 months, Gilead Sciences has paid 1.10 billion in taxes.

Income Tax	1.10B
Effective Tax Rate	13.13%

Stock Price Statistics

The stock price has increased by +33.58% in the last 52 weeks. The beta is 0.39, so Gilead Sciences's price volatility has been lower than the market average.

Beta (5Y)	0.39
52-Week Price Change	+33.58%
50-Day Moving Average	109.40
200-Day Moving Average	100.72
Relative Strength Index (RSI)	74.10
Average Volume (20 Days)	193

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Gilead Sciences had revenue of EUR 25.08 billion and earned 7.25 billion in profits. Earnings per share was 5.77.

Revenue	25.08B
Gross Profit	19.77B
Operating Income	9.91B
Pretax Income	8.34B
Net Income	7.25B
EBITDA	12.26B
EBIT	9.91B
Earnings Per Share (EPS)	5.77

Balance Sheet

The company has 9.03 billion in cash and n/a in debt, with a net cash position of 9.03 billion.

Cash & Cash Equivalents	9.03B
Total Debt	n/a
Net Cash	9.03B
Net Cash Per Share	n/a
Equity (Book Value)	19.26B
Book Value Per Share	15.52
Working Capital	6.88B

Cash Flow

Operating Cash Flow	8.53B
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Margins

Gross margin is 78.83%, with operating and profit margins of 39.52% and 28.90%.

Gross Margin	78.83%
Operating Margin	39.52%
Pretax Margin	33.27%
Profit Margin	28.90%
EBITDA Margin	48.91%
EBIT Margin	39.52%
FCF Margin	n/a

Dividends & Yields

This stock pays an annual dividend of 2.76, which amounts to a dividend yield of 2.19%.

Dividend Per Share	2.76
Dividend Yield	2.19%
Dividend Growth (YoY)	-3.19%
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	0.24%
Shareholder Yield	2.43%
Earnings Yield	4.72%
FCF Yield	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	7